Malignant neoplasm, pancreas

Disease

Some component of this panel might be part of the comprehensive metabolic panel.

Rule out cancer of islet cells.

EGFR is expressed 30-50% in Pancreatic ductal adenocarcinoma (PDAC). http://www.ncbi.nlm.nih.gov/pubmed/26361407

Not specific for pancreas cancer, but helpful in therapy treatment.

Alternative to Comprehensive Metabolic Panel.

Chemotherapy monitoring.

Determine therapeutic strategy for cancer therapeutics such as Tegafur.

Early detection of pancreatic cancer.

Please use “Pain Management Pharmacogenetics Gene Variation Panel” if testing ordered for pain management. This panel is comprehensive, and it is general and not specific for pain management.

Therapy selection and management.

If iron is low due to anemia.

Alternative to specific genetic markers. Good for therapy selection and monitoring.

If hemoglobin is low due to anemia.

If hemoglobin is low due to anemia.

Aid in the diagnosis and management.

Supportive in diagnosis and treatment.

Supportive in diagnosis and treatment.

Supportive in diagnosis and treatment.

Supportive in diagnosis and treatment.

Alternative to specif gene markers. Good for therapy selection and monitoring.

IF iron is low due to anemia.

Individual cancer test tissue specific is recommended.